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doi:10.1016/j.jfma.2011.09.024Among children, rotaviruses are the most common cause of severe gastroenteritis worldwide and
of diarrheal deaths in developing countries. Current vaccines (e.g., Rotarix, GlaxoSmithKline
Biologicals; RotaTeq, Merck and Company) effectively reduce rotaviral gastroenteritis, emer-
gency department visits, and hospitalizations. The tremendous burden of rotavirus-related
diarrhea in children across the world continues to drive the remarkable pace of vaccine devel-
opment. This review assesses the global epidemiological and economic burden of rotavirus
diseases, summarizes the relevant principles of the development of rotavirus vaccines, and
presents data on the efficacy and effectiveness of currently licensed vaccines in both devel-
oped and developing countries.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Rotavirus is the leading cause of severe gastroenteritis in
infants and young children worldwide. Globally, infection
results in more than 600,000 deaths each year in children
less than 5 years old who die from severe dehydration andof Public Health, College of
rsity, Number 1, University
.edu.tw (K.-T. Chen).
ight ª 2012, Elsevier Taiwan LLCelectrolyte and acid-base disturbances.1 It is estimated
that more than 80% of all rotavirus-related deaths occur in
resource-limited countries in south Asia and sub-Saharan
Africa.2 Nearly every child is infected with rotavirus by 5
years of age, irrespective of location (e.g., urban or rural
area) or socioeconomic status.3 Because improvements in
housing, water supply, sanitation, personal hygiene, food
quality, nutrition, and maternal education do not appear to
reduce the overall incidence of rotavirus infections, non-
fecal routes of infection may play a role in transmission.4
Consequently, vaccines are the most effective public
health intervention for the control of rotavirus disease.5& Formosan Medical Association. All rights reserved.
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economic burden of rotavirus disease, summarizes the
relevant principles of the development of rotavirus
vaccines, and presents data on the efficacy and effective-
ness of currently licensed vaccines in both developed and
developing countries. We searched MEDLINE, PubMed, and
The Cochrane Collaboration using ‘rotavirus’ and ‘rotavirus
vaccines’ as both the medical subject headings and
keywords. Articles not published in English were excluded
from this review.
Virology
Rotaviruses were discovered in animals in the 1960s.6 The
virus was first described in humans by electron microscopic
examination of duodenal biopsies from children with acute
gastroenteritis.7 The rotavirus, a 70-nm icosahedral virus
that belongs to the family Reoviridae and the genus
Rotavirus, is a nonenveloped, double-stranded RNA virus
that contains 11 segments of genomic RNA surrounded by
a triple-layered capsid.6,7 The viral genome encodes six
structural (VP1eVP4, VP6, and VP7) and six nonstructural
(NSP1eNSP6) proteins. The most abundant viral protein is
VP6, which bears the group-specific antigenic determinants
and forms the middle capsid layer; the outer-layer
proteins, VP7 and VP4, act as independent neutralizing
antigens. NSP4 is antigenic, allowing categorization into
different genotypes, and acts as an enterotoxin capable of
causing diarrhea.6
Within the Rotavirus genus, there are seven antigeni-
cally distinct serogroups (A through G), that are distin-
guished by different VP6 proteins. Group A rotaviruses are
the predominant cause of illness in humans and animals.6,7
There are two major outer capsid-surface proteins: VP7 and
VP4. These two proteins define the serotype of the virus
and are considered critical to vaccine development
because they are targeted by neutralizing antibodies that
may provide both serotype-specific and, in some instances,
cross-reactive protection.8 The VP7 protein is glycosylated,
and the serotypes determined by this protein are termed
“G serotypes.” VP4 is a protease-cleaved protein, and the
serotypes determined by this protein are termed “P sero-
types.” P serotypes are difficult to characterize using
traditional methods of virus neutralization; therefore,
molecular methods were used to determine its genotype
using sequence analysis.9 These genotypes correlate well
with the known serotypes, so the genotypes are tentatively
designated in brackets (e.g., P1B[8]).
Human rotaviruses exhibit enormous diversity. The gene
segments that encode the G and P proteins can indepen-
dently segregate, giving rise to strains with at least 42
different P-G serotype combinations10; however, a small
number of rotavirus strainsdthose bearing VP7 G serotypes
G1eG4 and G9 and VP4 P genotypes P1B[8], P2A[6], and P1A
[8]dare predominant worldwide.
Clinical illness
The severity of rotavirus infection is age-dependent.
Although the disease can occur at any age, clinically
significant incidents most commonly occur in young infantsand children.9,11,12 Rotavirus infections can range from
asymptomatic infection to mild diarrhea to severe gastro-
enteritis with dehydration. After an incubation period of
2e4 days, the symptoms typically abruptly begin with fever
and vomiting, followed by watery diarrhea lasting for 3e8
days.14,15 Compared with other viral enteropathogens,
rotaviruses are more likely to result in symptomatic illness
and lead to dehydration, electrolyte imbalance, and even
convulsions in severely ill patients.16,17 Fever was found
more commonly in patients with rotavirus gastroenteritis
than those with norovirus gastroenteritis.13e21
Following a severe episode of rotavirus-induced diar-
rhea, most children will shed the rotavirus within 1e3
weeks; however, approximately one in five will continue to
shed the virus for 4e8 weeks, especially if the child expe-
riences mild or intermittent gastrointestinal symptoms.22
Rotavirus disease is most common and severe in children
between 3e36 months of age.11,13 Multiple infections can
occur throughout life, although cumulative immunity
usually makes subsequent episodes mild or asymptomatic in
older children and adults.23 Rotaviruses are traditionally
believed to infect only the mature epithelial cells that line
the intestinal tract6; in contrast, clinical illness is
uncommon in neonates.24 The immaturity of the neonatal
gut, the presence of maternal antibodies, and the reduced
virulence of the rotavirus strains capable of replicating in
the neonatal gut may play a role in the asymptomatic
nature of neonatal infections.24 Meanwhile, rotaviruses are
associated with prolonged illness and stool shedding in
infants with severely compromised T-cell immunity and in
children and adults immediately following bone marrow
transplantation.25 Notably, children with asymptomatic or
symptomatic HIV infection and impaired immunity do not
appear to be at increased risk of developing severe rota-
virus disease, although they, too, may shed rotavirus
particles for longer than other children.26
The reported incidence of concomitant rotavirus and
Salmonella infection varies between 1.3e7.4%.27 Concom-
itant infection is associated with a more prolonged clinical
course, higher fever, higher incidence of green-colored
stool with blood and mucus, higher levels of C-reactive
protein (CRP), and a higher incidence of hypokalemia than
rotavirus infection alone.12e29 Rotavirus infection also
increases the risk of bacteremia in children with non-
typhoid Salmonella gastroenteritis.27Immunity
The immune correlates of protection from rotavirus infec-
tion and disease are still incompletely understood. Mouse
models have been extensively used to investigate the
contributions of different components of the immune
system to protect against rotavirus.30 These studies have
suggested that both humoral and cell-mediated immunity
are important in the resolution of ongoing rotavirus infec-
tion and in protection against subsequent infections.
The highest levels of serum rotavirus antigen are typi-
cally detected on day 2 of illness, with a gradual decrease
in antigen levels to nearly undetectable levels by day 6.31
The quantity of rotavirus antigen is significantly higher in
sera collected from patients with fever than in sera
Rotavirus infection 185collected from those without fever.32 Nonetheless, the
clinical significance of extraintestinal rotavirus infection
other than for fever associated with viremia or antigenemia
is unknown. The impact of antigenemia on the develop-
ment of natural and vaccine-induced immunity has not yet
been determined.33 A study by Desselberger and Huppertz34
examined the immune responses to natural rotavirus
infection and rotavirus vaccination in both experimental
animals and humans as potential correlates of protection.
Transmission
Rotaviruses are highly contagious. The infectious dose is
low (as few as 10 particles),35 and the virus is shed in large
quantities (as many as 1011 particles per gram of stool) both
before the onset of symptoms and for several weeks
afterward.22 Furthermore, the virus can survive on dry
surfaces for more than 10 days and on human hands for up
to 4 hours.36 Transmission to susceptible individuals occurs
mainly by the fecal-oral route through direct contact with
the rotavirus, including children and adults with asymp-
tomatic illness and contact with contaminated fomites,
food, water, and environmental surfaces.37,38 It has been
reported that improvements in hand hygiene in hospitals
can decrease the incidence in healthcare-associated rota-
virus infections.16,39 It has also been suggested that aerosol
transmission might be important.40,41 Evidence of the
airborne spread of rotavirus gastroenteritis is primarily
circumstantial, including the short incubation period (1e3
days) and the fact that the virus often presents in explosive
outbreaks.42 Rotavirus has also been detected in the
respiratory secretions from a small number of patients,43,44
and cases of pneumonia have been described. In addition,
some studies have noted the presence of respiratory
symptoms and otitis media in up to 50% of patients with
rotavirus.45 The preliminary findings from RNA obtained
from air samples taken from the rooms of hospitalized
children with rotavirus infections suggest that airborne
spread may be a major route of transmission in hospital and
day-care settings.46
Rotavirus epidemics exhibit a seasonal pattern.11 In
temperate climates, rotavirus infections peak in the winter
months. Seasonality is less marked closer to the equator,
but the disease is more common during drier and cooler
months. Recent data suggest that the seasonality of rota-
virus could have been changed by the introduction of
rotavirus vaccines.47,48
Disease burden
Acute gastroenteritis is second only to pneumonia as the
leading global cause of childhood mortality and morbidity,
accounting for 15% of all deaths in children less than 5 years
of age.49 The disease is estimated to be associated with the
deaths of more than 600,000 children per year worldwide,
with the majority of these deaths occurring in Africa and
Asia50; more than half of these deaths occur in only six
countries: India, Nigeria, Congo, Ethiopia, China, and
Pakistan.49 Most deaths occur in malnourished infants living
in socioeconomically disadvantaged rural regions in these
low-income countries, where access to healthcare is poor.49While deaths from rotavirus are rare in developed
countries in North America, Europe, East Asia, and
Australia, the incidence of disease in young children is
similar to that of developing countries.2 In the pre-rotavirus
vaccine era, rotavirus gastroenteritis resulted in 220,000
annual hospital admissions, 1.8 million healthcare visits,
and 7.1 million episodes of diarrhea among children living in
developed countries.1,2 By 5 years of age, approximately 1
in 50 children from these countries will have been hospi-
talized following rotavirus infection.1,2 In the United
States, for example, rotaviruses were responsible for 20e60
deaths, 410,000 physician visits, 205,000e272,000 emer-
gency department visits, and 55,000e70,000 hospitaliza-
tions each year during the 1990s and early 2000s.51 Thus,
between 1 in 67 and 1 in 85 children in the United States
will be hospitalized with rotavirus infection by the age of 5
years.51 Meanwhile, prior to the introduction of the rota-
virus vaccine in Taiwan, rotavirus was estimated to have
caused more than 150,000 cases of gastroenteritis, 106,000
clinic visits, 12,800 emergency department attendances, as
many as 15,000 hospitalizations, and almost 7 deaths each
year between 2000e2005.52e56 Most (>90%) of case of
rotavirus diarrhea occurred in children less than 5 years of
age (Fig. 1).
The annual societal costs due to rotavirus infection were
almost $US 900 million in the United States in 2004,57 $US
21.5 million in Taiwan in 2005,52 and V550 million in the
European Union in 2002.58 In comparison, a total societal
cost of only $US 423 million was reported for all developing
countries in 2007.59Global surveillance of rotavirus
As rotavirus vaccination continues to increase in prevalence
worldwide, global surveillance of rotavirus has become an
important tool. Surveillance is used to describe serotype
distributions in different countries and their regions,
identify and predict the development of emerging strains,
monitor the impact of vaccines by identifying successes and
gaps, and identify the causes of diarrhea other than rota-
virus. In 2002, the World Health Organization (WHO) and
the US Centers for Disease Control and Prevention (CDC)
developed a generic protocol for the standardized surveil-
lance of rotavirus, with a focus on severe diarrhea requiring
hospitalization among children less than 5 years of age60,61;
this protocol was first implemented in Asia.62 With the
support of the Rotavirus Vaccine Program (RVP), the
implementation of this protocol was expanded to include
the Americas, the eastern Mediterranean region, eastern
Europe, and sub-Saharan Africa.61 In recent years, these
systems have generated data from 196 sites in 59 countries
throughout the world (Fig. 2).63 This regional surveillance
model has led to improved data standardization, increased
visibility and perceived validity of data, and, potentially,
improved sustainability of the surveillance platforms.
The results of the global surveillance program using the
common generic protocol demonstrate that, among chil-
dren hospitalized for severe diarrhea in different regions of
the world, 39% (regional median) test positive for rota-
virus.61 Although the percentage of diarrhea cases that are
positive for rotavirus ranges from 20e73% in individual
Figure 1 Hospitalized patients with acute gastroenteritis by age in Taiwan, 2001e2003 (from reference 54, used with
permission).
186 S.-C. Chen et al.countries, the predominant role of rotavirus as a cause of
severe diarrhea is consistent across all regions.
Rotavirus surveillance also generates valuable data on
the circulating rotavirus strains (Table 1). These data are
vital to improving vaccine development, tracking emergent
types, and helping to assess vaccine effectiveness and
changes in strain diversity after vaccines are introduced.
Globally, G1, G2, G3, G4, and G9 are the most prevalent
VP7 serotypes; P[4], P[6], and P[8] are the most common VP4
genotypes, and G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8]
comprise 70e90% of circulating rotavirus strains.64e68 In
Taiwan, G1 (40%), G3(27%), G9 (18%), and G2 (8%) are the
most common VP7 serotypes.69e75
Strain diversity is the greatest in Africa and Asia, where
mixed infections with multiple rotavirus strains and
proximity to domestic animals that also shed the rotavirus
are common.66 In addition to regional differences, major
changes in one or more dominant circulating genotypes can
occur from one season to the next.76 Both G9 and G12 haveFigure 2 Rotavirus surveillance- countries participating in the W
WHO regions and partners).emerged and spread globally over the past decade.77
Multiple rotavirus serotypes can circulate within the same
region at the same time. Therefore, continued surveillance
of rotavirus strains remains important to monitoring the
molecular epidemiology of rotavirus infection and the
efficacy of vaccination.Rotavirus vaccines
Immunity to rotavirus infection in infants was first demon-
strated by Bishop et al,78 who observed that newborns
infected with rotavirus were protected against severe
diarrhea following reinfection. The development of rota-
virus vaccines has mainly focused on the delivery of live-
attenuated rotavirus strains by oral administration. The
most extensively evaluated approach is the “Jennerian”
concept, which involves immunization of infants with an
animal rotavirus considered to be naturally attenuated inHO network and reporting data for 2009. (Data collected from
Table 1 Geographic distribution of rotavirus serotypes.
Region Rotavirus serotypes
G1P[8] G2P[4] G3P[8] G4P[8] G9 Other
North America 73% 11% 6% 1% 3% 5%
Australia 82% 14% 1% 2% 0.5% 0.1%
Europe 72% 9% 2% 11% 4% 1.4%
South America 34% 23% 2% 9% 16% 11%
Asia 34% 13% 1% 20% 12% 14%
Africa 23% 2% 21% 4% 7% 27%
Taiwan 40% 80% 27% 0% 18% 8%
Sources: references 67e78.
Rotavirus infection 187humans.79 More recently, human rotaviruses attenuated by
passage in cell culture have been developed and tested.11
Finally, rotaviruses recovered from asymptomatic human
neonates, which may be naturally less virulent, are being
developed as oral vaccine candidates.80
Vaccines based on animal rotaviruses
Monovalent animal-strain vaccines
Three nonhuman rotavirus vaccines, two bovine rotavirus
strains, RIT4237 (P6[1] G6) and Wistar Calf 3 (WC3, serotype
P7[5]G6), and simian (rhesus) rotavirus reassortant vaccine
(RRV) strain MMU18006 (P5B[3]G3) have been studied.81e85
The RIT4237 bovine strain was isolated from a calf and
attenuated in cell culture. Although the initial efficacy trials
in Finland appeared promising, subsequent studies showed
little or no protection against rotavirus infection.83,84
The WC3 bovine strain was isolated from a calf in
Pennsylvania in 1981. These vaccines demonstrated vari-
able efficacy in field trials but produced particularly
disappointing results in developing countries.81,82
In 2000 and 2001, China introduced the Lanzhou lamb
rotavirus vaccine (LLR) for childhood immunizations.86 The
LLR vaccine, a monovalent (P[12]G10) live-attenuated oral
vaccine derived from a lamb strain of rotavirus, was
developed and produced by the Lanzhou Institute of Bio-
logical product, Lanzhou, China.
Evidence of the efficacy of LLR is derived from a case-
control study that was performed in Guangzhou province
that enrolled 838 children aged 2 months to 5 years who
were hospitalized with rotavirus infections and 838
community-matched controls.86 The study demonstrated
a 73% (95% CI: 61e82%) efficacy for one dose of LLR against
hospitalized rotavirus diarrhea. Immunological studies on
children aged 6e24 months before and after vaccination
showed that LLR induced neutralizing antibodies (range:
40e70%) against all G-type rotaviruses.87
LLR has never been tested in a randomized, placebo-
controlled phase III clinical trial,86 so the true efficacy of
the vaccine is unknown. In all of the reported trials, the
majority of children were vaccinated during or after
the peak age for rotavirus disease. It is unknown whether
the vaccinated children had prior infection with a natural
rotavirus, in which case LLR could simply have boosted
a pre-existing immune response.87 It is currently licensed in
China to be given to children aged 2e36 months, withyearly boosters.87 Between 2001e2008, approximately 10
million doses were administered in China.87 The vaccine is
not routinely being used in national immunization programs
in China or elsewhere.
Human-animal reassortant vaccines
In view of the inconsistent protection conferred by mono-
valent animal rotavirus-based vaccines, vaccine develop-
ment efforts began to focus on either naturally attenuated
human rotavirus strains or reassortant rotavirus strains with
the human rotavirus gene for the VP7 protein together with
the other 10 genes from an animal rotavirus strain.88 The
next generation of vaccines was formulated to include
more than one rotavirus G serotype in order to provide
heterotypic as well as homotypic immunity. The ability of
rotaviruses to reassort during mixed infections in vitro
allowed the production of reassortant vaccines, in what
was termed the “modified Jennerian” approach.79 The goal
was to evoke an immune response to a G-type antigen from
a human virus. Reassortants were initially created by
co-infecting a monkey with bovine and human rotaviruses
and allowing the reassortment to occur by chance. Subse-
quent reassortants were created in laboratories and prop-
agated in Vero cells.89
Human-animal rotavirus reassortants contain the gene(s)
that encode VP7, with or without VP4, derived from their
human rotavirus parent; however, the remaining genes are
derived from the animal rotavirus parent. These reassorted
viruses were developed as vaccine candidates. They could
induce immune responses in human capsid proteins while
still maintaining the attenuated properties of the parent
strain.88 Several reassortant vaccines based on either simian
or bovine strains have been produced and tested.88,89Quadrivalent human-rhesus reassortant
vaccine
The first multivalent, live, orally administered, reassortant
vaccine developed was RotaShield (a rhesus rotavirus
tetravalent [RRV-TV] vaccine). This tetravalent vaccine
contains a mixture of four virus strains representing the
most commonly seen G types (G1eG4): three rhesus-human
reassortant strains containing the VP7 genes of human
serotypes G1, G2, and G4 strains were substituted for the
VP7 gene of the parent RRV, and the fourth strain contained
the serotype G3 of rhesus RRV.88 Efficacy trials were con-
ducted, and the vaccine elicited 57e76% protection against
all forms of rotavirus-induced diarrhea and 82e96%
protection against severe rotavirus disease.89 RotaShield
was associated with a short duration of fever after the first
vaccination; however, no other adverse events were
commonly associated with the vaccine at the time of
licensing.90
This vaccine was licensed in the United States in 1998;
however, use of the vaccine was suspended and ultimately
withdrawn in 1999 after investigations demonstrated
a significant association between the vaccine and an
elevated risk of intussusception.91 The risk of intussuscep-
tion was 1 per 100,000 vaccinated persons, and cases were
clustered mostly within 3e14 days of the first dose. The risk
of intussusception appeared to be highest in those receiving
188 S.-C. Chen et al.their first dose after 3 months of age.92 The exact associ-
ation between RotaShield and intussusception remains
unclear; however, the error has made it necessary for
subsequent candidate rotavirus vaccines to undergo large
field trials, not only to prove efficacy in the absence of
a reliable correlate to protection, but also to demonstrate
safety (less than a 1 per 100,000 risk of intussusception).76
As an added precaution, strict vaccination schedules have
been implemented, requiring the first dose to be adminis-
tered between 6e14 weeks of age, and no “catch-up”
schedules are allowed. Moreover, several countries have
introduced post-licensing monitoring of intussusception.93Human-bovine rotavirus reassortant vaccine
Like RRV, the WC3 vaccine strain was developed in a series
of human-bovine reassortant vaccine strains, which were
then combined into a polyvalent vaccine.94 Compared
with the rhesus reassortants, the bovine-human reassor-
tants appear to cause less fever while still maintaining
immunogenicity.95
RotaTeq is a pentavalent, live-attenuated, human-
bovine reassortant oral vaccine developed by Merck & Co.,
Inc., Whitehouse station, NJ, USA. This vaccine contains
five live reassortant rotaviruses representing the most
common human VP7 types (G1eG4) and the attachment
protein (P7[5]) from the WC3 bovine rotavirus parent
strain.78,79 The fifth reassortant virus expresses the
attachment protein (P1A[8]) from the human rotavirus
parent strain and the G6 outer capsid protein from the
bovine rotavirus parent strain.72,96 RotaTeq is administered
in three oral doses at 1- to 2-month intervals, beginning at
6e12 weeks of age.96
Table 2 outlines the major phase III trials on human
rotavirus efficacy in various settings.89,97e104 A large
efficacy trial on RotaTeq has been completed: the study
found 74% and 98% efficacy against all and severe forms of
disease, respectively.105 RotaTeq also has efficacy against
each of the common circulating serotypes. A large safety
trial with more than 70,000 infants and various subgroup
analyses, including a large European cohort,96,106 shows
that RotaTeq has high efficacy for covering the main period
of risk for rotavirus gastroenteritis, reduces rotavirus
gastroenteritis-associated hospitalization and emergency
department and physician visits, and shows no evidence of
increased risk of intussusception following vaccination
compared with placebo recipients. An efficacy and safety
trial conducted in developing countries also shows that the
vaccine reduces healthcare-resource utilization attributed
to rotavirus gastroenteritis in infants without increased
risk of intussusception or other serious adverse events.107
Khoury et al projected the effectiveness of the RotaTeq
vaccine against rotavirus gastroenteritis-related (RGE)
hospitalizations and deaths in six Asian countries (China,
Hong Kong, India, South Korea, Taiwan, and Thailand) using
a simple mathematical model. The model projected an
overall effectiveness in the range of 82e89% against
RGE-related hospitalizations and a substantial reduction in
RGE-related deaths.104
Merck has received approval for RotaTeq in the United
States, and the vaccine was recommended by the AdvisoryCommittee on Immunization Practices (ACIP) for the
routine immunization of infants in 2006.108 Post-marketing
surveillance data from the United States have not identi-
fied any concern, such as association with intussusceptions
or Kawasaki disease, related to the safety of RotaTeq.109
UK-based bovine-human reassortant vaccine
Another multivalent bovine-human reassortant vaccine has
been independently developed by the National Institute of
Allergy and Infectious Diseases (NIAID). This bovine rota-
virus tetravalent (BRVTV) vaccine incorporates four reas-
sorted viruses with a single gene for VP7 (G1, G2, G3, or G4
human serotype) and 10 genes from the UK bovine rotavirus
strain (P[7]G6). In a trial in the United States, the vaccine
demonstrated satisfactory levels of attenuation, safety,
infectivity, and immunogenicity for each monovalent
reassortant in infants.110 Its development has been taken
over by manufacturers in Brazil, India, and China.
Human rotavirus-strain vaccines
The human rotavirus strains that have been developed as
vaccines or vaccine candidates are either attenuated
common strains or uncommon strains that have been iso-
lated from asymptomatic neonates.
Monovalent human G1-rotavirus vaccine
A live-attenuated human rotavirus vaccine strain (strain
89-12) was originally obtained from an infant with rotavirus
infection in Cincinnati, OH, by tissue culture passage of
a wild-type human rotavirus isolate.111 This vaccine is a P1A
[8]G1 strain and, thus, represents the most common human
rotavirus VP7 and VP4 antigens. The vaccine was further
developed by Avant Immunotherapeutics and licensed to
GlaxoSmithKline Biologicals, who further modified it by
cloning and tissue culture passaging of the parent 89-12
vaccine strain112: the result was the RIX4414 vaccine
(Rotarix) (Table 2). Rotarix showed high efficacy in early
trials in the United States and Finland.112 The vaccine has
been tested in Latin America, and the first results from
these multicountry trials were reported in Mexico, Brazil,
and Venezuela, where efficacy against severe rotavirus
disease was 86%.113 Efficacy has been confirmed in a series
of trials that enrolled more than 63,000 children. In these
studies, efficacy against hospitalization was 85% and effi-
cacy against non-G1 serotypes was 75%.113 A large efficacy
and safety trial that enrolled more than 15,000 healthy
infants aged 6e13 weeks from 10 Latin American countries
has reported a vaccine efficacy of 81e82% against wild-type
G1, 78% against pooled non-G1 strains, 81% against pooled
non-G1P[8] strains, 83% against hospital admission for
rotavirus gastroenteritis, and 39% against admission for
diarrhea of any cause.114 No significant adverse events or
increased risk of intussusception were observed among the
vaccine recipients.114 The vaccine was first licensed in
Mexico and the Dominican Republic in 2004, and it was also
licensed in the United States in 2008 when the vaccine was
recommended by the ACIP for inclusion in the routine
Table 2 Efficacy of live-attenuated oral rotavirus determined in randomized, double-blind, placebo-controlled clinical trials.
Vaccine Year
reported
Location Efficacy against Efficacy （95％
confidence intervals）
Reference
RotaShield 1996 USA Rotavirus episodes 49% [98]
Very severe episodes 82%
Dehydrating illness 100%
RotaShield 1997 Finland RVGE of any severity 68% (57e76) [89]
Severe RVGE 91% (82e96)
RotaRix 2006 European countries RVGE of any severity 87% (80e92) [97]
Severe RVGE 96% (84e100)
RotaRix 2009 Singapore Severe RVGE 96% (85e100) [100]
RotaRix 2010 Malawi, South Africa Severe RVGE 61% (44e73) [103]
RotaTeg 2006 Argentina, Brazil, Chile, Colombia, the
Dominican Republic, Honduras, Mexico,
Nicaragua, Panama, Peru, Venezuela,
Finland
Severe RVGE and
rotavirus-associated
hospitalizations
85% (71e93) [99]
RotaTeg 2010 Ghana, Kenya, Mali RVGE of any severity 31% (17e42) [101]
Severe RVGE 39% (19e55)
RotaTeg 2010 Bangladesh, Vietnam RVGE of any severity 43% (21e58) [102]
Severe RVGE 48% (22e66)
RotaTeg 2011 China, Hong Kong, India, South Korea,
Taiwan, Thailand
Sever RVGE 82e89% [104]
RVGE, rotavirus gastroenteritis.
Rotavirus infection 189immunization of infants.108 As of May 2007, Rotarix had
been approved in 90 countries worldwide.
RV3 neonatal-strain vaccine
RV3, a P2A[6]G3 strain, was first isolated in newborns at the
Children’s Hospital in Melbourne, Australia.115 The devel-
opment of this vaccine was based on an observation that
neonates in hospital nurseries who were infected with this
rotavirus strain were usually asymptomatic and later pro-
tected against severe disease in early childhood. Initial
safety trials, in which a single dose of the vaccine was used,
demonstrated no significant adverse events; however,
serum immune responses were poor.87 A trial using three
doses of vaccine did induce immune responses in 54% of
infants, and the vaccinated children who developed
immune responses were protected from rotavirus disease.
Because of these promising results, the developers are
working with BioPharma (Bandung, Indonesia) to increase
the titer of this vaccine and then return to clinical trials.
Indian neonatal-strain vaccines
Two strains isolated from newborns in India are currently
being prepared as potential vaccines. Strain 116E, isolated
in 1985 from an outbreak of asymptomatic rotavirus infec-
tions in New Delhi, is a P8[121] G9 natural reassortant
between a human parent strain and a VP4 gene of bovine
origin.116 The sequence of the VP4 gene is homologous to P
[11], a genotype commonly found in cattle. A nosocomial
outbreak of infection at a maternity center in Bangalore led
to the identification of another “outbreak” of strain I321,
also a bovine-human reassortant strain.117 Unlike strain
116E, strain I321 has a base of nine bovine gene segments;only gene segments 5 and 7, which encoded nonstructural
proteins 1 and 3, respectively, were of human origin. A
strain with the same G and P segments as strain I321 has
since emerged as a cause of diarrhea in children in Vellore,
India.118Other approaches to rotavirus vaccination
Nonspecific (innate) and acquired virus-specific humoral
and cellular immune responses are elicited by rotavirus
infection or rotavirus vaccination.33,119 The immunological
mechanism by which protection against rotavirus disease
occurs after natural infection or after immunization is
unknown.120 Rotavirus infection results in the production of
both serum and intestinal antibodies and protects against
severe diarrheal illness on subsequent infection.120,121 The
difficulty in understanding the mechanism of protection has
complicated the interpretation of various clinical trials, in
which variable efficacy results were obtained. In brief,
most studies on immune responses have indicated that the
presence of fecal IgA or serum antibodies serves as a good
surrogate marker for protection,122 although other effector
mechanisms of the immune response are believed to be
important. These mechanisms are undefined in humans at
the present, although animal studies point to the impor-
tance of CD4 and CD8 T cells.30
Although orally administered live virus vaccines repre-
sent the primary approach to rotavirus vaccine develop-
ment, other approaches and routes of administration are
being evaluated and tested in animal models. Work on virus-
like particles, cold-adapted strains, inactivated strains, and
DNA vaccines is ongoing.123e125 These approaches could
have some advantages in the future if they could improve
the variable immune response to oral vaccines, be
190 S.-C. Chen et al.combined with other parenterally administered vaccines, or
avoid the risk of intussusception.
Conclusion
Rotavirus is responsible for a substantial disease burden
in infants, parents, and communities worldwide. Rotavirus
vaccination provides a high degree of protection against
severe rotavirus gastroenteritis and is the best available
choice for the prevention of disease. The challenges of the
rotavirus vaccination program in the developing world are
many and ongoing: these challenges include the limited
availability of vaccine, the necessity of “cold chain”
delivery to the population, and the need for comprehensive
diarrheal control by improving water quality, hygiene, and
sanitation.
The evolving story of rotavirus vaccines is unique in
that these new lifesaving vaccines have been initiated
simultaneously in developed and developing countries.
Continued surveillance is necessary if these vaccines are to
contribute to reducing childhood mortality by one-third
from 1990e2015, in accordance with the United Nations
Millennium Development Goals. Ongoing epidemiologic
surveillance will be used to determine whether observed
regional differences in serotype data will help in the
development of new vaccines; in the future, new vaccines
will be needed if rotaviruses become able to evade current
vaccine immunity. Surveillance data should also be used to
assess rotavirus immunization programs in developing and
developed countries from the perspective of public health
and policy and to elicit support from governments for
preventive medicine programs.
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